drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (TCR-T)
drug_description
Autologous, gene-edited TCR-T cell therapy engineered to express an HLA-A*11:01–restricted TCR specific for the KRAS G12D neoantigen; administered as an infusion with dose escalation to mediate antigen-specific cytotoxicity against KRAS G12D–mutant tumors.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Adoptive Immunotherapy
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-edited to express an HLA-A*11:01–restricted TCR specific for the KRAS G12D neoantigen. After infusion, these engineered TCR-T cells recognize KRAS G12D peptide–MHC I complexes on tumor cells, activate via TCR signaling, and kill target cells through antigen-specific cytotoxic mechanisms (e.g., perforin/granzyme).
drug_name
RE002 T cell
nct_id_drug_ref
NCT06546150